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PREFACE
Ubiquitous albeit enigmatic, the prostaglandins
bear medical promise for the future. Their role in
physiochemistry and mode of action remain obscure though
many of their effects have been recognized. In particular,
prostaglandin F2 has been shown to excite uterine smooth
muscle and, in fact, to mimic oxytocin. The oxytocic
properties have led to obstetrical investigation of its
possible use for the induction of labor.
This study evolved as an offshoot of an investigation
carried out by the Department of Obstetrics and Gynecology,
Yale University School of Medicine and the Yale-New Haven
Hospital, by Drs. Gerald G. Anderson, John C. Hobbins, and
Leon Speroff. In developing a protocol to compare prosta
glandin F2 and oxytocin (and later a second prostaglandin,
E2) as labor-inducing agents in humans, they extended to
Dr. Marcello M. Orzalesi and to Dr. Michael G. Blackburn
the invitation to investigate the possible effects of
these agents on the neonate.
I should not have engaged in this investigation had
it not been for Drs. Orzalesi and Blackburn who generously
invited my participation in the study. I, therefore, remain
indebted in the first instance to Drs. Anderson, Hobbins,
v
vi
and Speroff for opening the avenues to such research. More
over, I must extend my gratitude and appreciation to Dr.
Orzalesi who encouraged me and advised me in the develop
ment of this research into my doctoral thesis. In due
course, I wish to render thanks to. Dr. Blackburn for his
role in teaching me the elements of design of a research
protocol, in inuring me to the principles and subtleties
of clinical investigation, and in helping me to analyze
the data and to prepare the final manuscript.
Also, I wish to acknowledge the support of Mrs.
Penelope Pigram and Mrs. Elaine Grey, Research Assistants,
who assisted in the collection and orderly recording of the
laboratory data.
***********
This study was supported in part by NIH Grant FR00125
and USPHS Grants FR05358 and 1T01HD00177.
H. M.-U., Jr.
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INTRODUCTION
In order to insure the health and well-being of both
mother and infant during parturition, circumstances often
compell the obstetric practitioner to seek some means of
either accelerating or even inducing labor. Consequently,
numerous methods and medicaments have been employed to
this end over the course of medical history.
Within the last century, obstetrical practice has
developed the relatively safe and effective use of oxy
tocin, a hormone elaborated by the pituitary and released
during parturition, which only lately has begun to reveal
its natural function. Within the past decade, however,
progress in experimental technique has allowed both
laboratory and clinical investigators to examine a new
class of bioactive substances, the prostaglandins. Early
observations in reproductive physiology have subsequently
led investigators to explore the possible advantages that
these hormone-like substances might enjoy over oxytocin in
inducing labor. Accordingly, since the administration of
any drug to a pregnant woman raises the question of possible
harm to her fetus, the application of prostaglandins to the
induction of labor has made essential a detailed evaluation
of the potential toxic effects of these drugs on the fetus
and newborn infant. This study intends to explore such
1
2possibilities and to enumerate the effects on the neonate
of one prostaglandin, prostaglandin F2 -
HISTORICAL PERSPECTIVE
Obstetricians have long sought a safe and reliable
means of electively inducing labor in both term and preterm
pregnancies.1 Indeed, long before the days of the formally
trained obstetrician, primitive man attempted to bring on
or hasten labor by such non-operative means as compression
of the abdomen and shaking the bedstead or stool that held
the laboring mother-to-be; he even resorted to snuff and
less direct routes of therapy. Elaborating the latter, the
Chinese as long ago as 3000 B.C. and until the seventeenth
century A.D. employed the fumes of boys' urine mixed with
vinegar and poured over hot bricks. Similarly, the Hindus
from 1500 B.C. to A.D. 500, in addition to feeding the gra
vid female simple gruel as a medicament, offered the woman
the fumes of smouldering skin of black snakes.
Not until the sixteenth century after the birth of
Christ did any semblance of scientific methodology appear
in the induction of labor. In fact, Ambroise Pare (1510-
1590) is reputed to have been the first to successfully
induce labor by accouchement force in cases of uterine
hemorrhage. Yet, almost a century elapsed until Francois
Mauriceau (1637-1709), a fellow countryman of Pare, intro
duced the practice of artificially rupturing the membranes
3
4in cases of placenta previa in an attempt to control
hemorrhage. His procedure, the amniotomy, gradually gained
the acceptance of physicians over Pare ' s method of forced
dilatation of the cervix. In 1756, G. Macaulay, a Briton,
first performed an amniotomy to induce labor prematurely
in a pregnancy threatened with cephalo-pelvic dispropor
tion as term approached.2 However, Macaulay 's contribution
was first popularized some thirty years later in 1785 by
Thomas Denman in his Principles of Midwifery or Puerperal
Medicine . No doubt, the obvious risk of introducing in
fection into the womb by amniotomy prompted James Hamilton
in 1810 to suggest using the examining fingers to merely
separate the membranes from the uterine wall without
rupturing them. Hamilton later reconsidered his position
and instead proposed introducing a catheter-sheated stilet
into the uterus in place of the examining fingers to perform
the amniotomy but at a higher level.
Numerous other methods of inducing labor were tried
in the nineteenth century and subsequently abandoned.2
Ergot was prescribed by some physicians who only found it
produced uterine spasm and endangered the fetus. Herder
suggested galvanism in 1803. Kiwisch and later Cohen (1846)
experimented with vaginal and intra-uterine injections of
hot water; this procedure precipitated fetal cardiac and
pulmonary complications. Finally, in 1853 Albert Krause
modified Hamilton's original suggestion and inserted bougie
tubes between the membranes and uterine wall. Although
5the bougie procedure remained a standard for some seventy
years, circa 1850 a similar instrument, the metreurynter,
gained favor. These inflatable rubber bags, developed by
men such as Tarnier, Barnes, and Voorhees, were inserted
in the vagina and uterus. The procedure, however, neces
sitated that the cervix be dilated a minimum of two finger-
breadths. Unfortunately, the required dilatation caused
many zealous obstetricians to be too forceful when inserting
the bags, and induction with the metreurynter often
approached that of accouchement force of Pare. Ultimately,
both the bougie and the metreurynter fell out of favor by
the 1930' s; and artificial rupture of the membranes, first
introduced in the seventeenth century, was reintroduced as
the preferred method of inducing labor.
In 1920, Benjamin P. Watson of Toronto, Canada, read
his paper to the American Gynecological Society estab
lishing the medical induction of labor with oxytocics.
Prior to that time quinine, introduced in Europe in the
seventeenth century, had long been known to augment the
contraction of spontaneous labor. Larger doses had then
recently been prescribed at term in the hope of actually
inducing labor. Blair Bell as early as 1909 had first
employed extracts of the pituitary gland in obstetrical
practice, and Watson in 1913 had reported on three
successful inductions. However, in 1920 Watson brought
forth some one hundred fifty cases 'of induced labor com
paring bougies, metreurynters, quinine, pituitary extract,
6and quinine plus pituitary extract.3 He concluded that the
method of using pituitary extract with or without quinine
had "a definite place in obstetric practice and should be
considered before other methods are adopted." Two years
later, he reported the results of one hundred ninety-five
cases in which he gave pituitary extract to induce labor
with a ninety per cent success rate.1*
Over the course of the next four decades the desicated
posterior pituitary gland of cattle and swine gave way to
pure extracted oxytocin and later to synthetic oxytocin.
During the late 1940 's Theobald et. al.5 and Helman6 repor
ted their experiences with the intravenous administration
of oxytocin to induce labor.
As the use of oxytocin increased, investigators began
to enumerate its hazards. Even among the one hundred
ninety-five cases that Watson reported in 1922, ten still
births and two neonatal deaths occurred within three days
after birth. Among the twelve deaths, three were associated
with hydrocephalus or anencephalus . However, Watson also
attributed two deaths to pulmonary atelectasis and three to
cerebral hemorrhage. As late as 1958, Keetel et. al.7 not
only reproved as unsafe the elective induction of labor in
general but condemned the use of oxytocin. They concluded
that when and if necessary, simple amniotomy or artificial
rupture of the membranes remained the most effective means
of inducing labor. Primarily, they noted an increased
7perinatal mortality associated with infection following a
prolonged induction. They also observed an increased
incidence of prematurity. Furthermore, they implicated
oxytocin as the cause of other complications, specifically
prolapse of the cord, malpresentation, and precipitous
delivery with intracranial hemorrhage. In 1963, Niswander
and Patterson8 noted a significant increase in respiratory
distress, as well as the greater tendency for the cord to
prolapse, when labor was electively induced with oxytocin
in combination with amniotomy. Besides the risks to the
fetus, other investigators have reported maternal complica
tions, among them tetanic contractions, amniotic fluid
embolism, and post partum hemorrhages.9
The use of oxytocin continued to gain acceptance,
nevertheless. In 1965, O'Leary and O'Leary9 demonstrated
the safety and efficacy of a prescribed regimen of oxytocin
when administered by intravenous infusion to selected
mothers. In particular, they observed a decrease in the
perinatal morbidity and mortality previously reported by
others.
The fact remains that medical indications for elective
induction of labor frequently arise in the practice of good
obstetrics. Hence, a more reliable agent for inducing labor
with a higher success rate and with fewer complications,
particularly in the preterm pregnancy, is highly desireable.
THE PROSTAGLANDINS
Within the past few years new reports on the bio-
activity of the prostaglandins have virtually inundated
the medical literature. In 1971 alone, some four hundred
reports appeared.10 The exact role of these substances
in reproduction and parturition has remained in question
ever since their discovery by Goldblatt1
x and von Euler12
in the early 1930 's. Each man, working independently,
reported on a substance found in human semen that acted
as a potent vasopressor and stimulant to uterine and
tubal motility. They suggested the name prostaglandin
in the erroneous belief that it originated in the prostate
gland. Further investigation, however, eluded general
interest until Bergstrom and his associates13 described
the basic chemical structure in 1962. They discovered
that prostaglandin actually comprised a number of compounds,
all arising from an hypothetical 20-carbon structure,
prostanoic acid. Subsequent investigations have revealed,
so far, fourteen different prostaglandins; thirteen of these
occur in man.
Each prostaglandin appears to induce one or more
physiological or biochemical responses that may in turn be
antagonized or, indeed, complemented by yet another prosta-
8
9glandin. Often seemingly indiscriminate, they may affect
several organ systems simultaneously. Furthermore, the
individual prostaglandins found in any tissue vary according
to the organ system and species.11*' 15 Despite their often
paradoxical functions, the regulatory activity of the prosta
glandins has encouraged multi-lateral research into their
possible therapeutic use. The experimental data unfortu
nately engenders some confusion because of the species
specificity of each prostaglandin. A detailed discussion
of these responses falls beyond the scope of this report.
Several monographs and collected works are available though
their material lags behind the more recent advances in the
field.16"20
Early prostaglandin research suffered because the
purified compounds eluded isolation in sufficient quantity.
Initially, Bergstrom extracted prostaglandins from frozen
sheep seminal vesicles amassed in Iceland, Greenland, and
Norway.21 Both he and the Upjohn Company, which funded his
endeavor, soon realized the need for a more plentiful source.
In 1964 Bergstrom' s laboratory at the Karolinska Institute,
the Upjohn Laboratories in the U.S.A., and a third group,
Unilever Research Laboratories in the Netherlands, simul
taneously discovered that incubating ovine vesicles with
certain essential fatty acids would produce prostaglandins.22
The Upjohn Company soon perfected the process. In fact, in
1970 alone, the company dispensed to various investigators
throughout the world over eleven hundred lots of prosta-
10
glandins prepared by this enzymatic process.22 In the same
year Upjohn scientists also achieved the total synthesis
of the fatty acid derivatives and began to modify the
naturally occurring compounds, thereby opening a new area
of research. Recently, Bundy et. al. at Upjohn developed
a process that utilizes the outer cortex of Plexaura
homomalla (Esper) , "an otherwise undistinguished member of
the group of marine invertebrates known as gorgonians . "
2 '
The value of this latter mode of synthesis remains to be
established.
In the field of reproductive physiology, several
investigators have used prostaglandins F2 , E2, and Ei
(PGF2 , PGE2, and PGEi) because of their oxytocin-like ef
fects to induce labor with varying degrees of success.
However, no accompanying reports have appeared in the
literature that critically assess the effects on the
neonate of the induction of labor with prostaglandins.
Using PGF2 , Karim and associates reported on eight
infants born by induced labor in 196823 and another thirty-
three in 1969. 2"* Both studies limited comments on the
status of the neonate to Apgar scores and general clinical
impressions. Karim et. al.25 published a third report in
1970 on experiments with PGE2. In the latter study, he and
his co-workers successfully induced forty-six of fifty
women. Yet, the authors gave only the birth weights of the
infants. Similarly, Beazley et. al.26 reported only the
11
Apgar scores following their experiences with PGE2 in forty
inductions; and Embrey27 gave no mention of the status of
the neonates in publishing his data on the use of both
PGEi and PGE2 in twenty-three successful and two unsuc
cessful inductions. Roberts and Turnbull28 compared
three prostaglandins, PGF2 , PGE2, and PGEi. While they
noticed a significant increase in uterine hypertonus with
PGE2, they limited mention of the neonates to the comment
that two infants of low birth weight (one PGEi and one PGE2
induction) developed the respiratory distress syndrome.
Recently, Beazley and Gillespie29 published results of
a double-blind study comparing PGE2 to oxytocin in two hun
dred six live-born infants. They too confined their analy
sis of the neonate to the Apgar scores, noting no difference
between the two groups. Following Beazley and Gillespie's
study, Craft et. al.30 also compared PGE2 and oxytocin.
Although not using the double-blind approach, they com
pared fifteen PGE2 to fifteen oxytocin inductions and noted
an increased incidence in type-2 decelerations of the fetal
heart rate during labor in the group induced with PGE2.
However, fetal blood sampled to evaluate the significance
of these decelerations, showed a pH less than 7.20 in only
one instance. As in previous reports, analysis of the in
fant during the neonatal period did not go beyond Apgar
scores. In the oxytocin group, four infants had one-minute
Apgar scores of 7 or less, although only two demonstrated
type-2 decelerations during labor. All four had Apgar
12
scores of 8 or greater at five minutes of age. Among the
prostaglandin-induced infants, only three scored 7 or less
at one minute. Two of the three had decelerations of the
fetal heart rate during labor. Of those two, one had a five-
minute Apgar score of only 4; the other two scored 10 at
five minutes. The authors suggest that they could possibly
have minimized the untoward effects on the fetus had they
reduced the infusion rates of both agents after the membranes
had ruptured. They offered no conclusion regarding the
effects of either drug on the neonates.
The purpose of this study was to investigate the
possible effects of induction of labor with PGF2 on the
newborn infant by evaluation of both clinical and bioche
mical parameters.
MATERIAL AND METHODS
Without forehand knowledge as- to the agent employed
for the induction of labor (PGF2 or oxytocin) , infants
were admitted to the study from a larger, double-blind
investigation on the induction of labor.31'
32 Since under
certain circumstances the indications for induction of
labor, as well as unexpected complications arising during
delivery, might in themselves have an untoward effect on
the status of the neonate, the study included only infants
born to multiparous mothers and excluded all cases with the
risk of serious fetal or maternal jeopardy. Less hazardous
obstetric complications, when present, were recorded for
later reference. The infused doses of the inducing drugs
were titrated in the mother over the period of induction.
The dose of PGF2 ranged from an initial 1.5 yg/min to
40 yg/min at four hours. That for synthetic oxytocin began
as low as 1.0 mU/min and was increased to 16 mU/min by four
hours. The reader is referred to the obstetrical literature
cited above for further details.
The present study includes twenty-three infants, eleven
born after induction of labor with PGF2 , and twelve with
oxytocin. The double-blind aspect of the investigation
was maintained until completion of the clinical and
13
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biochemical evaluations, at which time the code was first
broken. (See Table I for a summary of obstetrical histories.)
Since the half-life of circulating prostaglandins is
only a matter of minutes for the F-group,33' 3 4 it was felt
that an acute period of intense observation during the first
six hours of life, followed by a re-evaluation at forty-
eight to seventy-two hours of age, would yield representa
tive data. In addition to a general physical examination,
recording Apgar scores, and monitoring vital signs and cli
nical appearance, several metabolic parameters were measured
at regular intervals after birth, arbitrarily defined as
the moment of complete delivery of the thorax. Notation
was made of the time elapsed until the first breath. A
section of the umbilical cord was double-clamped immediate
ly after delivery for arterial and venous sampling. The
infant was rapidly placed in a standard heated bassinet in
the delivery room and given a thorough physical examination.
Particular note was made of the time when the arterial
pulse of the umbilical stump ceased. Apgar scores at one
and five minutes were calculated with notation of respira
tory and heart rates. Bathing of the infant was deferred
until after the acute study period of six hours. Each
infant was transferred to the Newborn Special Care Unit
as soon as possible after completion of Apgar scoring and
placed in a pre-warmed, servo-controlled Isolette set at
36.5°C.
Upon arrival in the Unit, the infant received an
15
antero-posterior chest roentgenogram taken by the direct
magnification technique.35 Chest roentgenograms were
repeated at the end of the acute study period (six hours)
and again at the time of the follow-up examination (third
day) . After application of the monitoring equipment, the
neonate was not handled nor stimulated throughout the
study except for the collection of capillary blood samples.
All vital signs were measured at half-hourly intervals
from the time of birth. The electrocardiogram was monitored
using standard bipolar limb leads. Respirations were
counted by observing the thoracic excursions. The systolic
blood pressure and heart rate were measured using an
infant oscillometer with a mercury sphygmomanometer and
two pneumatic cuffs applied to the right arm. The tempera
ture was continuously recorded by means of a thermistor
probe inserted approximately three centimeters into the
rectum.
Blood samples from the double-clamped section of
umbilical cord were immediately collected in the delivery
room. Blood from the umbilical arteries was drawn into
heparinized syringes for evaluation of pH, P , P , base
excess and lactate content. Venous cord blood was used
for determination of hemoglobin, hematocrit, and white
blood cell count, as well as serum sodium, potassium, and
blood glucose levels. An additional heparinized aliquot
was set aside for assaying PGF2 levels in plasma. At one,
two, and six hours of life, capillary blood specimens were
obtained by heel stick and analyzed for pH, P , base
16
excess, hemoglobin, hematocrit, sodium, potassium, and
glucose. A final capillary sample was drawn between
forty-eight and seventy-two hours of life for estimation
of pH, P , base excess, and total serum bilirubin
concentration.
Hemoglobin was measured in duplicate by the cyan-
methemoglobin method using a Beckman DU Spectrophotometer.
Hematocrit was measured in quadruplicate using Clay-Adams
Microhematocrit Tubes centrifuged for ten minutes at seven
thousand rpm. White blood cell counts were made in a
standard counting chamber. The pH, P , P , and baseC 0 2 0 2
excess were determined using a Radiometer pH Meter 22 and
an Astrup AMT 1 Micro Tonometer system. Blood lactate
levels were determined by the Lactate UV-Test (Boehringer)
on 1.0 ml of blood from the umbilical artery, which had been
immediately precipitated in 1.0 ml of 0.6 N perchloric
acid. Blood glucose levels were determined by the
Glucostat method. Total serum bilirubin determinations were
carried out in triplicate using an Advanced Jackson
Bilirubinometer . Serum sodium and potassium determina
tions were carried out with an Instrumentation Laboratory
Flame Photometer Model 143.
Levels of PGF2 in the plasma of cord blood were
measured by a radioimmunoassay carried out in the
Department of Obstetrics and Gynecology of Yale University.36
RESULTS
The means and standard deviations of all vital signs
monitored at birth and at half-hourly intervals for the
first six hours of life appear in Table II. Table III
lists the means and standard deviations of the parameters
studied on both umbilical and capillary blood samples
collected at birth, at one, two, and six hours, and on the
third day of life. Apgar scores and other clinical data
appear in Table I.
As a part of the obstetrical study in progress,32
PGF2 levels were measured in ten samples of umbilical
cord blood selected at random, five from each induction
group (PGF2 and oxytocin) . The average PGF2 level was
higher in the cord bloods from the group induced with PGF2 .
(See Fig. 1 and Table III.) However, the difference did
not reach statistical significance.37
In spite of the disparity in umbilical PGF2 levels,
all other parameters studied failed to yield significant
differences between the two groups of infants and followed
the expected course of normal neonatal adaption.38' 39
The Apgar scores at one and five minutes were not less
than 8 for any infant and showed a comparable distribution
for both groups (Table I) . Furthermore, the duration of the
17
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umbilical pulse varied widely irrespective of the drug ad
ministered for the induction. The results of the physical
examinations carried out in the delivery room and on the
third day were normal in all infants of either group. In
addition to the vital signs, clinical observation disclosed
no apparent differences between the two groups in general
activity, feeding and sleep patterns (Fig. 2) , micturition
and bowel movements (Fig. 3).
A review of the roentgenograms of the chest taken
within thirty minutes after birth, at six hours, and at
follow-up examination on the third day revealed no radio
logic evidence of pulmonary or cardiac anomalies. Both
groups of infants demonstrated the expected radiologic
appearance of gradual and complete expansion of all areas
of the lung and resorption of residual fluid.
The electrocardiograms of all infants were reviewed
and were all considered to be normal.
DISCUSSION
This investigation was designed to evaluate the
possible clinical and metabolic effects of the induction
of labor with prostaglandin F2 on infants during the
early neonatal period. As previously mentioned, the
medical literature of recent years contains numerous
references regarding the effects of PGF2 on various
organ systems. The parameters evaluated in this
study were chosen in an effort to document a number
of these effects in the neonate.
Clinically, the physical examination and Apgar
scores confirmed the findings previously reported by
Karim:23' 2k all infants appeared normal; all Apgar
scores fell within normal limits.
PGF2 has been shown by many investigators to be a
potent hypertensive agent in dogs, where it causes
vasoconstriction thus increasing systemic and pulmonary
arterial pressures. It also exerts a positive inotropic
effect on the myocardium and increases cardiac output
as well as systemic venous return.1*0-1*6 Karim et. al.1*7'
"*
and Carlson et. al.,1*9 however, have amply demonstrated
that PGF2 , in the dosage used for the induction of labor,
has no effect on human heart rate, blood pressure, or
19
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electrocardiogram. Accordingly, the present study revealed
no descernible effects on heart rate, systolic blood
pressure, or electrocardiogram in the neonate.
The human respiratory system does respond to PGF2 .
In 1968 Sweatman and Collier50 demonstrated in vitro a
dose-related increase in the contraction of isolated
human bronchial muscle. Subsequently, Hedqvist and
associates51 established the potency of low doses of PGF2
in vivo. Indeed, they found that the prostaglandin
produced a significant decrease in airway conductance.
This information relates well to the experimental results
obtained with PGF2 in dogs wherein dynamic lung compliance
drops sharply in response to bronchoconstriction •
5 2' 53
Respiratory rate has also been found to be affected in
dogs.1*5'1*6 Working with guinea pigs, Piper and Vane5"*
have shown that PGF2 is released during anaphylaxis. In
the newborn human, however, none of these effects became
evident. The interval from delivery of the thorax to the
first breath, the respiratory rate and pattern during
the first six hours of life, the chest x-rays, and the blood
gas analyses disclosed no differences between the two study
groups .
Since several prostaglandins including PGF 2 have been
identified in the human umbilical cord, Karim hypothesized
that prostaglandins might play a role in constricting the
cord vessels at birth.5 Furthermore, since PGF2, has been
21
shown to have a direct effect on peripheral vessels, its
administration during labor could conceivably alter
placental circulation and thereby produce fetal hypoxia.
It could also affect the volume of placental transfusion
at birth, thus altering the blood volume of the infant.
These possibilities, however, were not borne put by the
results obtained in cord blood, which showed similar pH,
base excess, and lactate levels, as well as hematocrit
and hemoglobin concentrations in the two groups of infants.
Also, the fact that serum bilirubin levels on the third day
of life were similar in both groups of infants suggests that
PGF2 had no major effect on circulating blood volume, the
rate of hemolysis, and liver function of the infant. Final
ly, the duration of pulse in the umbilical stumps of the
infants showed no difference between the two groups. In
short, the data obtained do not support the initial set
of hypotheses.
Roberts and his associates56 have shown that PGF2
a
lacks the anti-diuretic properties of oxytocin. They
suggested that PGF2 might have a particular advantage over
oxytocin as an inducing agent in pregnant women with evi
dence of either pre-eclampsia or renal disease. In obser
ving the neonate, however, micturition patterns as well as
serum sodium and potassium levels failed to reveal descer-
nible differences. Possible effects of PGF2 on visceral
a
smooth muscle were also considered. Neither the number of
22
bowel movements nor micturition patterns suggested a
stimulatory effect on intestinal peristalsis or bladder
tone.
Within the spectrum of smooth muscle stimulation,
Davies and Withrington5 7 found that PGF2 consistently
decreased splenic volume in the dog. In an effort to
detect a concomitant shift in blood volume, the hemoglobin,
hematocrit, white blood cell count, sodium, and potassium
values were compared in the two groups of infants. These
parameters disclosed no differences suggesting an effect.
Furthermore, as mentioned earlier, serum bilirubin levels
determined on the third day revealed no evidence of hyper
emia, hyperhemolysis , or decreased liver conjugating
activity.
All newborn infants demonstrate a drop in blood
glucose followed by a gradual. rise during the early neo
natal period. Therefore, blood glucose levels were
determined at regular intervals on the theoretical assump
tion that either alterations in hepatic perfusion or un
known effects on metabolism might interfere with glucose
homeostasis. No such variations were found. The absence
of any significant changes thus conforms to the negative
findings of Spellacy et. al.58 who examined maternal
carbohydrate metabolism. Lactate levels also failed to
reflect any adverse effect of PGF2 on glucose metabolism.
The latter finding falls in sharp contrast to the data
23
obtained from studies in dogs wherein arterial lactate
has been found to be markedly increased following admini
stration of PGF2 ,1*6
a
Although to date PGF2 is the only prostaglandin
found in the brain,17 its function in the central nervous
system remains obscure.59-62 In the present investigation,
the administration of PGF2 produced no detectable effect
on the behaviour of the neonate. Neurologic examinations
and sleep-wake patterns fell within normal limits for all
infants.
Most of the effects of the prostaglandins on the
various organ systems are dose-related. Since the cord
prostaglandin level was only moderately elevated in the
group of infants whose mothers were induced with PGF2 ,
it is likely that the lack of demonstrable side effects
on the neonate is at least due in part to the dosage
employed in this study.
Turnbull63 has remarked on the accumulation of data
that implicates the fetal pituitary-adrenal axis as the
source of the mechanism ultimately controlling the onset
of labor. Accordingly, Chard61* has consistently demon
strated by means of radioimmunoassay that the fetus
itself releases oxytocin during labor. Perhaps the ul
timate discovery of the exact role the prostaglandins
play in the control of labor and their relationship with
24
oxytocin will explain, too, why the artificial induction
of labor with prostaglandin F2 produces no effects on
the neonate distinguishing it from induction with
oxytocin.
CONCLUSION
Based on the clinical and metabolic parameters studied
in the present investigation, prostaglandin F2 appears to
have no direct effect on the fetus or neonate that distin
guishes it from oxytocin when administered to the mother
for the induction of labor in full-term, uncomplicated
pregnancies .
25
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CLINICAL —
PARAMETER P 0 P0 POPOPOPO PO
Heart Rate M 155 163 157 177 141 149 135 140 130 137 134 131 130 124
(/min.) S.D. 26 20 13 19 15 19 10 10 10 8 12 10 10 14
Respiratory Rate
(/min. )
M
S.D.
45
8
50
10
54
7
59
14
55
22
54
14
57
20
59
13
62
17
55
17
48
15
54
15
52
21
49
13
Blood Pressure
(mmHg)
M
S.D.
74
13
73
8
72
12
79
9
68
14
74
8
64
8
71
9
66
8
71
8
67
12
71
7
Temperature
(5C)
M
S.D.
35.7
0.7
35.7
0.5
36.1
0.9
36.1
0.7
36.6
0.6
36.4
0.7
36.8
0.5
36.6
0.6
36.8
0.4
36.7
0.5
AGE
3 hr. 3*- hr. 4 hr. 4% hr. 5 hr . 5V hr . 6 hr.
PO POPO PO PO PO PO
Heart Rate
(/min. )
M
S.D.
133
19
126
9
i31
15
128
13
130
11
127
14
130
12
131
14
131
16
132
15
131
14
135
11
130
14
138
17
Respiratory Rate
(/min. )
M
S.D.
50
19
48
15
51
15
46
18
48
17
51
17
55
23
47
16
59
23
50
19
57
22
52
21
56
25
53
20
Blood Pressure
(mmHg)
M
S.D.
68
8
69
8
68
0
69
7
67
8
69
7
70
7
71
8
67
8
72
9
67
6
73
7
GS
7
72
7
Temperature
(°C)
M
S.D.
36.8
0.4
36.9
0.3
36.8
0.5
36.9
0.4
36.8
0.4
36.8
0.4
36.9
0.4
36.8
0.4
36.9
0.5
36.9
0.4
37.0
0.7
37.0 '
0.5
36.8
0.5
37.1
0.4
TABLE II. RESULTS (MEAN [M] AND STANDARD DEVIATION [S.D.]) OF CLINICAL OBSERVATIONS
PERFORMED AT VARIOUS AGES IN INFANTS BORN AFTER INDUCTION OF LABOR WITH
PGF2 (11 subjects [P]) OR OXYTOCIN (12 subjects [0])
AGE
LABORATORY
PARAMETER
Cord 1 h,Dur 2 hours 6 hours 48-72 hrs..
P O P O P O P O P O
Hemoglobin
(g./lOO ml.)
M
S.D.
16.1
2.7
17.4
1.7
18.8
2.9
19.4
1.9
18.6
2.5
19.9
2.2
17.5
2.1
18.3
2.0
Hematocrit
(%)
M
S.D.
46.0
6.0
50.4
• 6.4
57.7
8.2
57.1
4.1
53.5
e.4
59.0
4.8
50.5
6.1
53.3
4.3
PH M
S.D.
7.33
0.06
7.32
0.08
7.34
0.06
7.33
0.06
1,. 40
0.04
7.40
0.04
7.40
0.05
7.44
0.04
7.47
0.08
7.43
0.06
CO 2
(mmHg)
M
S.D.
38.0
6.0
39.7
6.3
39.8
7.9
44.2
9.2
35.5
4.9
36.9
5.4
32.3
6.0
31.1
6.9
23.9
7.5
31.3
5.5
Base Excess
(mEq./L.)
M
S.D.
-5.7
2.8
-5.6
3.5
-4.2
2.9
-2.9
2.5
-2.5
1.3
-1.3
2.1
-2.8
2.5
-2.1
2.1
-4.0
2.4
-2.'0
2.7
Sodium
(nEq./L.)
M
S.D.
139.6
8.7
134.6
5.6
139.8
7.7
141.4
5.1
142.5
5.9
142.7
6.0
143.7
8.1
142.6
5.0
Potassium
(mEq./L.)
M
S.D.
6.8
1.5
6.9
0.9
6.2
0.9
5.7
0.7
5.7
0.7
5.9
0.8
5.8
0.9
5.9
0.3
Glucose
(mg./lOO ml.)
M
S.D.
80.5
13.7
70.0
23.5
49.6
17.8
39.6
13.8
59.2
11.9
41'. 9
8.5
63.4
16.3
49.6
17.5
Lactate
(mEq./L.)
M
S.D.
24.3
7.7
19.6
5.4
OnmHq)
M
S.D.
27
11
24
9
White Blood
Coll Count
(/mm3.)
M
S.D.
11,500 14,400
PGF..
dig. /ml.)
M
S.D.
7.20
1.80
4.75
2.00
Totnl Bilirubin
(mg./lOO ml.)
M
S.D.
4.1
1.8
6.6
4.0
TABLE III. RESULTS (MEAN [M] AND STANDARD DEVIATION [S.D.]) OF LABORATORY STUDIES
PERFORMED AT VARIOUS AGES IN INFANTS BORN AFTER INDUCTION OF LABOR
WITH PGF2 (11 subjects [P]) OR OXYTOCIN (12 subjects [O])
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